Literature DB >> 396084

Response of arterial blood pressure, plasma renin activity and plasma aldosterone concentration to long-term administration of captopril in patients with severe, treatment-resistant malignant hypertension.

C S McCaa, H G Langford, W C Cushman, R E McCaa.   

Abstract

1. The response of arterial blood pressure, plasma renin activity and plasma aldosterone concentration to inhibition of angiotensin I converting enzyme (kininase II) with captopril has been studied in patients with severe, treatment-resistant, malignant hypertension. 2. Nine patients with a past history of severe hypertension, supine diastolic blood pressure greater than 120 mmHg before conventional antihypertensive therapy and resistant to conventional antihypertensive therapy were studied. 3. Captopril administration resulted in a marked decrease in arterial blood pressure and plasma aldosterone concentration and an increase in plasma renin activity. 4. Although arterial blood pressure remained significantly below the values observed during the control period, pressure did tend to increase again after 3 days. Addition of hydrochlorothiazide kept arterial pressure significantly below pretreatment control values.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 396084     DOI: 10.1042/cs057371s

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  4 in total

1.  The approach to the treatment of hypertensive patients with renal parenchymal disease.

Authors:  L U Mailloux; P A Bluestone; R T Mossey
Journal:  Bull N Y Acad Med       Date:  1982-03

2.  Long-term experience with captopril in severe hypertension.

Authors:  J Havelka; H J Boerlin; A Studer; P Greminger; W Tenschert; T Luescher; W Siegenthaler; W Vetter; P Walger; H Vetter
Journal:  Br J Clin Pharmacol       Date:  1982       Impact factor: 4.335

Review 3.  Captopril: a preliminary review of its pharmacological properties and therapeutic efficacy.

Authors:  R C Heel; R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1980-12       Impact factor: 9.546

Review 4.  Managing resistant hypertension: focus on mineralocorticoid-receptor antagonists.

Authors:  Juan Carlos Yugar-Toledo; Rodrigo Modolo; Ana Paula de Faria; Heitor Moreno
Journal:  Vasc Health Risk Manag       Date:  2017-10-16
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.